Trial Profile
Open-label, Phase I/II study to evaluate pharmacokinetics, pharmacodynamics, safety, and anticancer activity of avelumab in pediatric subjects from birth to less than 18 years of age with refractory or relapsed solid tumors and lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary)
- Indications Astrocytoma; CNS cancer; Lymphoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors EMD Serono Research & Development Institute; Merck KGaA
- 01 Oct 2022 Results (n=21; data cutoff date: 27 Jul 2021) reporting dose-escalation data published in the Cancer Immunology Immunotherapy
- 29 Apr 2022 Patients from this study were used to evaluate the pharmacokinetic modeling simulations was developed for dose selection, published in the Clinical Pharmacokinetics
- 03 Dec 2021 Status changed from active, no longer recruiting to completed.